Journalartikel

Jahr der Veröffentlichung: 2016

Seiten: 648-652

Zeitschrift: Urologe A

Bandnummer: 55

Heftnummer: 5

ISSN: 0340-2592

eISSN: 1433-0563

DOI Link: https://doi.org/10.1007/s00120-016-0088-3

Verlag: Springer

Abstract: 
Not only has the use of tyrosine kinase inhibitors (TKI) for the treatment of metastatic renal cell carcinomas (mRCC) changed the therapeutic options for this disease significantly, but with the occurrence of typical side effects this therapy also poses a challenge for the treating physician. Fatigue und hypothyroidism are two common side effects of TKI therapy that can often appear simultaneously. By reducing the patients' quality of life these side effects often lead to a discontinuation of therapy. With this review we want to give the treating physician an overview of the classification and the specific treatment of TKI-induced fatigue and hypothyroidism in order to maximize patients' compliance and the therapeutic efficacy of TKI therapy.

Harvard-Zitierstil: Sikic, D., Luedecke, G., Lieb, V. and Keck, B. (2016) Side effect management of tyrosine kinase inhibitors in urology. Fatigue and hypothyroidism, Urologe A, 55(5), pp. 648-652. https://doi.org/10.1007/s00120-016-0088-3

APA-Zitierstil: Sikic, D., Luedecke, G., Lieb, V., & Keck, B. (2016). Side effect management of tyrosine kinase inhibitors in urology. Fatigue and hypothyroidism. Urologe A. 55(5), 648-652. https://doi.org/10.1007/s00120-016-0088-3